Cure Forward Announces First Trial Recruitment Collaboration That Will Expand Patient Access To Innovative Treatments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cure Forward, an online precision medicine platform for cancer patients and their care teams, and Novartis Pharmaceuticals Corporation today announced that Cure Forward’s unique Clinical Trial Exchange will support Novartis in identifying potential patients for all of its current oncology trials.

“Cure Forward makes clinical trial enrollment easier and more accessible. Novartis’ bold approach of activating searches for oncology trials on our platform will help patients find possible investigational treatments for their care.”

The collaboration further validates Cure Forward’s approach for real-time patient sourcing in clinical trials. By utilizing its patent pending Clinical Trial Exchange, Cure Forward facilitates connections between patients and drug development companies, based on mutual criteria and preferences, comparable to popular online dating platforms.

There is a significant efficiency gap in the clinical trial process today, placing undue burden on patients and caregivers to navigate the vast, complex landscape of medical research options – often at stages in which their time is most valuable. Drug developers are concurrently developing investigational treatments, but often struggle to find the right patients to receive these investigational treatments.

Cure Forward’s platform empowers patients to govern their own care plans, providing accurate, easily accessible information to help drive individual choices.

“Today’s patient is active in his or her care, accessing data to make important treatment decisions,” said Martin Naley, Founder and Chief Strategy Officer, Cure Forward. “Cure Forward makes clinical trial enrollment easier and more accessible. Novartis’ bold approach of activating searches for oncology trials on our platform will help patients find possible investigational treatments for their care.”

For more information, please visit CureForward.com.

About Cure Forward

Cure Forward bridges the gap between patients and precision medicine, beginning in cancer. Cure Forward provides a simple-to-use platform that allows patients to obtain their genomic data and use it to identify treatment options including clinical trials, solving critical business needs for diagnostic laboratories, health care providers and clinical trial recruiters. Cure Forward is based in Cambridge, Massachusetts and was incubated and launched by Apple Tree Partners, New York City. The company’s platform is in beta release at www.cureforward.com.